A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
Phase 3
18+
Female only
1 site in FL
What this study is about
This Phase 3 study is testing Bevacizumab in people with neoplasms. The primary outcome being measured is Progression-Free Survival (PFS).
Simplified from trial records by PatientMatch.
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Assignment is predetermined by the study protocol.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
bevacizumab
infusion
Primary: Progression-Free Survival (PFS)
Secondary: Change From Baseline in Abdominal/Gastrointestinal (GI) Symptoms Combined Score Using the EORTC QLQ-Ovarian Cancer Module 28 (OV28), Change From Baseline in Global Health Status/Quality of Life (GHS/QoL) Combined Score (Items 29 and 30) Using the European Organisation for Research and Treatment of Cancer QoL Questionnaire-Core 30 (EORTC QLQ-C30), Change From Baseline in Physical Functioning Combined Score (Items 1 to 5) Using EORTC QLQ-C30, Change From Baseline in Role Functioning Combined Score (Items 6 and 7) Using EORTC QLQ-C30, Number of Participants Who Discontinue Study Treatment Due to an AE, Number of Participants Who Experience an Adverse Event (AE), Overall Survival (OS), Progression-Free Survival 2 (PFS2)
Oncology